Skip to content

US · ENVB · BIOTECHNOLOGY

Enveric Biosciences, Inc. (ENVB) intrinsic value and stock valuation

$1.35as of 2026-11-21 · Mkt cap 925.37K

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Enveric Biosciences, Inc. DCF and intrinsic value

InvestorsCraft values ENVB with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ENVB’s statements →

Enveric Biosciences, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Cambridge, MA 02142 enveric.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-12.13M
20112025
Free cash flow
-$-8.14M
20112025
Total equity
$4.18M+4.1% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-8.77M-$-9.63M-$-16.45M-$-19.96M-$-25.94M
Net income-$-12.13M-$-9.57M-$-20K-$-18.5M-$-48.98M
EPSd-$-36.76M-$-239.25M-$-111.11K-$-108.82M-$-1.22B
Operating cash flow-$-8.14M-$-7.73M-$-14.09M-$-17.15M-$-11.46M
Capital expenditure$0.00$0.00-$-10K-$-580K-$-860K
Free cash flow-$-8.14M-$-7.73M-$-14.1M-$-17.73M-$-12.32M
Total assets$5.1M$3.08M$4.3M$19.6M$26.7M
Total debt$0.00$0.00$0.00$60K$180K
Net debt-$-4.68M-$-2.24M-$-2.29M-$-17.66M-$-17.18M
Total equity$4.18M$1.59M$1.96M$15.6M$22.3M
Cash and short-term investments$4.68M$2.24M$2.29M$17.7M$17.4M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$200K$340K$410K$440K$680K
Gross profit-$-200K-$-340K-$-410K-$-440K-$-680K
Research and development expenses$2.78M$2.84M$7.25M$8.03M$4.79M
Selling, general and administrative expenses$5.79M$6.45M$8.79M$11.5M$20.5M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$8.57M$9.29M$16M$19.5M$25.3M
Cost and expenses$8.77M$9.63M$16.5M$20M$25.9M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$10K$10K
Depreciation and amortization$200K$340K$410K$440K$680K
Ebitda-$-8.57M-$-9.23M-$-16.85M-$-19.52M-$-55.74M
Operating income-$-8.77M-$-9.63M-$-16.45M-$-19.96M-$-25.94M
Total other income/expenses, net$0.00$70K-$-810K$0.00-$-30.49M
Income before tax-$-8.77M-$-9.57M-$-17.26M-$-19.96M-$-56.43M
Income tax expense$3.36M$10K$30K-$-1.49M-$-7.45M
Net income-$-12.13M-$-9.57M-$-20K-$-18.5M-$-48.98M
Weighted average shares outstanding$330K$40K$210K$210K$40K
Weighted average diluted shares outstanding$330K$40K$180K$170K$40K
Balance sheet
20252024202320222021
Cash and short-term investments$4.68M$2.24M$2.29M$17.7M$17.4M
Net receivables$0.00$0.00$220K$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$4.94M$2.73M$3.58M$18.4M$17.7M
Property, plant and equipment, net$160K$310K$510K$740K$470K
Goodwill and intangible assets$0.00$40K$210K$380K$8.51M
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$160K$350K$720K$1.12M$8.98M
Total assets$5.1M$3.08M$4.3M$19.6M$26.7M
Accounts payable$580K$520K$1.22M$460K$680K
Short-term debt$0.00$0.00$0.00$60K$110K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$920K$1.49M$2.34M$4M$2.08M
Long-term debt$0.00$0.00$0.00$0.00$70K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$0.00-$0.00$2.33M
Capital lease obligations$0.00$0.00$0.00$60K$180K
Total liabilities$920K$1.49M$2.34M$4M$4.41M
Common stock$10K$10K$30K$20K$10K
Retained earnings-$-114.85M-$-106.07M-$-96.5M-$-79.21M-$-60.74M
Accumulated other comprehensive income (loss)-$-580K-$-590K-$-570K-$-540K-$-30K
Total equity$4.18M$1.59M$1.96M$15.6M$22.3M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$0.00$0.00$0.00$60K$180K
Net debt-$-4.68M-$-2.24M-$-2.29M-$-17.66M-$-17.18M
Cash flow statement
20252024202320222021
Net income-$-8.77M-$-9.57M-$-17.29M-$-18.47M-$-48.98M
Depreciation and amortization$200K$340K$410K$440K$680K
Stock-based compensation$830K$1.56M$2.15M$2.62M$12.6M
Change in working capital-$-300K-$-420K-$-170K-$-220K$1.19M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-410K-$-830K-$-100K$260K$380K
Net cash provided by operating activities-$-8.14M-$-7.73M-$-14.09M-$-17.15M-$-11.46M
Investments in property, plant and equipment$0.00$0.00-$-10K-$-580K-$-860K
Acquisitions, net$0.00$0.00$0.00$960K$3.06M
Net cash used for investing activities$0.00$0.00$10K-$-580K$2.19M
Common stock issued$10.6M$2.29M$0.00$17.2M$21.6M
Common stock repurchased$0.00$1.08M-$-1.05M$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$10.6M$7.67M-$-1.34M$18.2M$24.9M
Net change in cash$2.44M-$-50K-$-15.44M$370K$15.8M
Cash at end of period$4.68M$2.24M$2.29M$17.7M$17.4M
Operating cash flow-$-8.14M-$-7.73M-$-14.09M-$-17.15M-$-11.46M
Capital expenditure$0.00$0.00-$-10K-$-580K-$-860K
Free cash flow-$-8.14M-$-7.73M-$-14.1M-$-17.73M-$-12.32M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Enveric Biosciences, Inc.

        Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.

        CEO
        Joseph Edward Tucker
        Employees
        6
        Beta
        1.14

        Explore

        Frequently asked questions

        What is the intrinsic value of Enveric Biosciences, Inc. (ENVB)?

        InvestorsCraft does not currently publish an intrinsic value for ENVB. How the IC value is calculated.

        Is ENVB undervalued?

        InvestorsCraft does not publish an undervaluation signal for ENVB at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.